FDA · guide

FDA Warning Letter vs Recall vs Import Alert: The Enforcement Ladder Explained

Updated September 1, 2026

The ladder at a glance

FDA's tools are not a strict sequence. The Regulatory Procedures Manual (RPM) says regulatory actions 'may be applied individually, sequentially, or concurrently', and a Warning Letter 'is not a prerequisite to taking enforcement action' (RPM Chapter 4; RPM Chapter 6). Still, most matters climb roughly this way:

Form FDA 483 observations

A Form FDA 483 'is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations' of the FD&C Act (FDA Form 483 FAQ). It 'does not constitute a final Agency determination'. FDA considers the 483 together with the Establishment Inspection Report, evidence collected on site and 'any responses made by the company' before deciding what further action, if any, is appropriate, and companies 'are encouraged to respond' in writing with a corrective action plan. A prompt, specific 483 response is the cheapest place on the ladder to stop climbing.

Untitled letters

An untitled letter 'cites violations that do not meet the threshold for significance of regulatory significance for a Warning Letter' (RPM Chapter 4, section 4-2-1). By design it is not titled, contains no warning that failure to correct may result in enforcement action, and 'requests (rather than requires)' a written response within a reasonable time, with 30 days given as an example.

Warning letters

The RPM is explicit about legal effect: 'A Warning Letter is informal and advisory. It communicates the agency's position on a matter, but it does not commit FDA to taking enforcement action', and FDA 'does not consider Warning Letters to be final agency action on which it can be sued' (RPM Chapter 4). Its function is to achieve voluntary compliance and to establish prior notice. The letter requests correction and 'a written response within a specific period of time after the date of receipt of the letter, usually fifteen (15) working days', and warns that failure to address the issues may result in regulatory or legal action. FDA posts letters in a searchable database with filters for issuing office, letter issue date, posted date, and whether a response or close-out letter exists (Warning Letters database). Posting lags issuance by days to weeks, so monitor the posted date, not the letter date.

Recall

A recall is the firm's 'removal or correction of a marketed product' that FDA considers violative (21 CFR 7.3). It is 'a voluntary action' and 'an alternative to a Food and Drug Administration-initiated court action', and FDA may request one; if a firm refuses an FDA-requested recall, seizure or other court action 'is indicated' (21 CFR 7.40). For devices FDA also holds mandatory recall authority under section 518(e), exercised through 21 CFR Part 810 when there is a reasonable probability of serious adverse health consequences or death (21 U.S.C. 360h(e)). Classified and 'not yet classified' recalls appear in the weekly Enforcement Report.

Import alerts and DWPE

Imports are judged on appearances. Section 801(a) allows FDA to refuse admission when 'it appears from the examination of such samples or otherwise' that an article is adulterated or misbranded, after an opportunity to introduce testimony (21 U.S.C. 381). An import alert tells field staff that FDA has enough evidence to allow detention without physical examination (DWPE) of products that appear violative. FDA's FAQ defines the lists: the Red List covers firms, products or countries 'which have met the criteria for Detention without Physical Examination', the Yellow List covers those subject to intensified surveillance, and the Green List covers those 'that have met criteria for exemption' (Industry FAQs for Import Alerts). Publication of the listing itself usually serves as notification under RPM 9-8. Removal requires a petition showing the underlying condition is resolved so that FDA has confidence future entries will comply (Removal from DWPE). FDA offers a weekly import alert summary by email.

Judicial actions: seizure, injunction and consent decree

Seizure is an in rem action against the goods: any 'adulterated or misbranded device' is 'liable to be proceeded against' and condemned in federal district court (21 U.S.C. 334). The same section lets FDA administratively detain a device found during an inspection for up to 20 days, extendable to 30 to institute a seizure. An injunction 'is a civil judicial process initiated to stop or prevent violation of the law, such as to halt the flow of violative products in interstate commerce, and to correct the conditions that caused the violation to occur' (RPM Chapter 6, section 6-2; 21 U.S.C. 332). Both are filed by the Department of Justice on FDA's behalf. Many cases end in a consent decree, a court-entered agreement negotiated with DOJ. In a seizure, the claimant may consent to a decree condemning the goods and providing for reconditioning under FDA supervision, backed by a penal bond of roughly twice the retail value, and the RPM notes that injunctive provisions may be added 'if recurrence of the same violations that resulted in the seizure is likely'. Consent decrees of permanent injunction typically impose multi-year obligations, outside audits and FDA cost recovery, and the RPM lists contempt, prosecution and civil money penalties among the responses to noncompliance with a decree.

Civil money penalties

For devices, section 303(f)(1)(A) authorizes civil penalties 'not to exceed $15,000 for each such violation' and 'not to exceed $1,000,000 for all such violations adjudicated in a single proceeding' as written in statute (21 U.S.C. 333). Those figures are inflation-adjusted each year by HHS in the table at 45 CFR 102.3, which at time of writing (September 2026) listed $35,466 per violation and $2,364,503 per proceeding (45 CFR 102.3); confirm the current year's table before relying on a number. The RPM names civil money penalties 'for example, for medical devices or tobacco products' among the actions available after a decree is violated (RPM Chapter 6).

Reading a company's position on the ladder

Look at the combination, not a single event. A 483 with no letter usually means FDA accepted the response. A warning letter with no close-out after a year, plus a recall in the Enforcement Report, is a firm under active scrutiny. An import alert red-listing is often the fastest commercial consequence for a foreign manufacturer because it bites at the border without a court. RegPing's FDA bot delivers warning letters, recalls and import alert notices into Discord so each rung is visible as it is posted.

Where to verify

• RPM Chapter 4: Advisory Actions
• RPM Chapter 6: Judicial Actions
• FDA Form 483 Frequently Asked Questions
• Warning Letters database
• Industry FAQs for Import Alerts
• 21 U.S.C. 334 seizure and administrative detention
• 21 U.S.C. 333 penalties

This guide is general information, not legal advice. Verify against the primary source and consult counsel before acting.